D.N.

DNAtrix is a clinical-stage biotechnology company specializing in the development of oncolytic virus immunotherapies for aggressive and difficult-to-treat cancers. The company's proprietary platform utilizes engineered adenoviruses designed to selectively infect and kill cancer cells while simultaneously triggering a systemic anti-tumor immune response. Its lead candidate, DNX-2401 (tasadenoturev), is an investigational oncolytic immunotherapy that has demonstrated promising results in clinical trials for recurrent glioblastoma and pediatric brain tumors. DNAtrix is also advancing a pipeline of armed viruses, such as DNX-2440, which expresses the OX40 ligand to further enhance immune activation within the tumor microenvironment.